We see pain as a disease,
not as a symptom
We understand pain is not just a symptom but also an entire condition in itself that requires specialised treatment.
We know that pain is different for everyone and the experience and symptoms depend not only on the type of condition, but also the individual patient.
By understanding how and why pain is generated in a variety of conditions we are driving development into innovative pain solutions that will have a truly meaningful impact on patient lives.
Our approach to understanding pain has three main areas of focus:
Select an area of focus for more information
Patients are central in the journey towards developing effective pain solutions.
Through our work with patient organisations and direct interactions with patients, we have been able to create tangible improved outcomes for patients.
Our patient-centred activities include:
Pain Days, Patient Days and Patient Summits allow us to listen to the patient perspective to better understand their experiences of living with a range of chronic pain conditions.
We have developed standardised tools, such as patient-reported outcome (PRO) measures and disease-specific questionnaires, in collaboration with patient groups.
By mapping the patient pathway from diagnosis to symptoms and treatments, we deepen our understanding of the day-to-day burden of disease and what a meaningful improvement in symptoms would look like to patients.
We capture patients’ feedback through protocol focus groups on clinical trial protocols. These help us to better understand and improve patient adherence, recruitment and retention in clinical trials.
Medical Expert Perspective
Expert knowledge from medical professionals and researchers is at the foundation of all our research.
Clinicians and medical experts help us to:
- Define patient phenotypes for whom treatments may be most effective
- Understand comorbidities associated with pain conditions, how these affect patient burden and treatment options
- Understand current treatment paradigms and unmet medical needs.
We have also worked with experts in the field to develop the PainSpectrum.
Basic Science Perspective
From patient and control tissues we are starting to identify which genes, RNAs, proteins or metabolites are involved in different disease characteristics.
This translational research leads to:
- Patient stratification/phenotyping for focused therapies
- Biomarkers for identified subgroups
- Pathway analysis for drug repurposing
- Novel ideas for target selection.
For example, our collaboration with the human genome specialists 23andMe, Inc. will enable us to survey more than 20,000 people and better understand genetic influences on pain, leading to more targeted and effective treatments in the future.